Use of anamorelin hydrochloride in a patient with lung cancer-related cachexia undergoing chemoradiotherapy: A case report

IF 0.2 Q4 ONCOLOGY Current problems in cancer. Case reports Pub Date : 2024-09-12 DOI:10.1016/j.cpccr.2024.100322

Haruka Fujioka , Kei Nakashima , Nana Munakata , Shigenori Yamamoto , Reina Idemitsu , Taiki Kawai , Kentaro Tochigi , Yasuhiro Morimoto , Hiroyuki Ito , Ayumu Otsuki

{"title":"Use of anamorelin hydrochloride in a patient with lung cancer-related cachexia undergoing chemoradiotherapy: A case report","authors":"Haruka Fujioka , Kei Nakashima , Nana Munakata , Shigenori Yamamoto , Reina Idemitsu , Taiki Kawai , Kentaro Tochigi , Yasuhiro Morimoto , Hiroyuki Ito , Ayumu Otsuki","doi":"10.1016/j.cpccr.2024.100322","DOIUrl":null,"url":null,"abstract":"<div><p>This report describes the case of a 59-year-old man with poorly differentiated lung adenocarcinoma and cachexia who completed chemoradiation therapy for stage III lung cancer following the administration of anamorelin. Anamorelin, a ghrelin receptor agonist, effectively improved his appetite and performance status, thereby enabling the continuation of treatment. The role of anamorelin in enhancing appetite during acute-phase treatment is promising; however, further studies must be conducted to elucidate its interaction with chemoradiation therapy. This case report highlights the potential of anamorelin as a therapeutic option for the management of cancer-related cachexia during curative treatment for lung cancer.</p></div>","PeriodicalId":72741,"journal":{"name":"Current problems in cancer. Case reports","volume":"16 ","pages":"Article 100322"},"PeriodicalIF":0.2000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666621924000450/pdfft?md5=863f25a88439439e21d5e29ef2a90d24&pid=1-s2.0-S2666621924000450-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current problems in cancer. Case reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666621924000450","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This report describes the case of a 59-year-old man with poorly differentiated lung adenocarcinoma and cachexia who completed chemoradiation therapy for stage III lung cancer following the administration of anamorelin. Anamorelin, a ghrelin receptor agonist, effectively improved his appetite and performance status, thereby enabling the continuation of treatment. The role of anamorelin in enhancing appetite during acute-phase treatment is promising; however, further studies must be conducted to elucidate its interaction with chemoradiation therapy. This case report highlights the potential of anamorelin as a therapeutic option for the management of cancer-related cachexia during curative treatment for lung cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

在接受化疗放疗的肺癌相关恶病质患者中使用盐酸阿那莫林：病例报告

本报告描述了一名患有分化不良肺腺癌并伴有恶病质的 59 岁男子的病例，他在服用阿那莫瑞林（anamorelin）后完成了 III 期肺癌的化疗。阿那莫瑞林是一种胃泌素受体激动剂，能有效改善他的食欲和表现状况，从而使治疗得以继续。阿那莫瑞林在急性期治疗中增进食欲的作用令人鼓舞；然而，还必须开展进一步研究，以阐明其与化疗放疗的相互作用。本病例报告强调了阿那莫瑞林作为治疗肺癌根治性治疗期间癌症相关恶病质的一种治疗选择的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊